Swathi Veeroju
Overview
Explore the profile of Swathi Veeroju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
119
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Novoyatleva T, Rai N, Kojonazarov B, Veeroju S, Ben-Batalla I, Caruso P, et al.
Commun Biol
. 2022 Jan;
5(1):97.
PMID: 35058570
No abstract available.
2.
Rai N, Sydykov A, Kojonazarov B, Wilhelm J, Manaud G, Veeroju S, et al.
Eur Respir J
. 2022 Jan;
60(2).
PMID: 35058248
Background: Pulmonary arterial hypertension (PAH) is a progressive disease characterised by pro-proliferative and anti-apoptotic phenotype in vascular cells, leading to pulmonary vascular remodelling and right heart failure. Peptidyl-prolyl / isomerase,...
3.
Novoyatleva T, Rai N, Kojonazarov B, Veeroju S, Ben-Batalla I, Caruso P, et al.
Commun Biol
. 2021 Aug;
4(1):1002.
PMID: 34429509
Pulmonary arterial hypertension (PAH), is a fatal disease characterized by a pseudo-malignant phenotype. We investigated the expression and the role of the receptor tyrosine kinase Axl in experimental (i.e., monocrotaline...
4.
Veeroju S, Kojonazarov B, Weiss A, Ghofrani H, Weissmann N, Grimminger F, et al.
Int J Mol Sci
. 2021 Feb;
22(3).
PMID: 33540939
Pulmonary hypertension (PH) is characterized by a progressive elevation of mean arterial pressure followed by right ventricular failure and death. Previous studies have indicated that numerous inhibitors of receptor tyrosine...
5.
Veeroju S, Mamazhakypov A, Rai N, Kojonazarov B, Nadeau V, Breuils-Bonnet S, et al.
PLoS One
. 2020 Jun;
15(6):e0234872.
PMID: 32559203
The leading cause of death in Pulmonary Arterial Hypertension (PAH) is right ventricular (RV) failure. The tumor suppressor p53 has been associated with left ventricular hypertrophy (LVH) and remodeling but...
6.
Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, et al.
Biomed Res Int
. 2019 Jan;
2018:7491284.
PMID: 30643819
No abstract available.
7.
Novoyatleva T, Kojonazarov B, Owczarek A, Veeroju S, Rai N, Henneke I, et al.
Am J Respir Crit Care Med
. 2018 Dec;
199(11):1407-1420.
PMID: 30557519
Pulmonary arterial hypertension (PAH) is characterized by vascular remodeling and excessive proliferation of pulmonary artery smooth muscle cells (PASMCs). Fucoidan, a polysaccharidic ligand of the adhesion molecule P-selectin, exhibits antiproliferative...
8.
Rai N, Veeroju S, Schymura Y, Janssen W, Wietelmann A, Kojonazarov B, et al.
Biomed Res Int
. 2018 Mar;
2018:3293584.
PMID: 29511676
Pulmonary arterial hypertension (PAH) is a progressive disorder characterized by remodeling of the pulmonary vasculature and a rise in right ventricular (RV) afterload. The increased RV afterload leads to right...
9.
Budas G, Boehm M, Kojonazarov B, Viswanathan G, Tian X, Veeroju S, et al.
Am J Respir Crit Care Med
. 2017 Sep;
197(3):373-385.
PMID: 28910144
Rationale: Progression of pulmonary arterial hypertension (PAH) is associated with pathological remodeling of the pulmonary vasculature and the right ventricle (RV). Oxidative stress drives the remodeling process through activation of...